Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 26, No 15S (May 20 Supplement), 2008: 3
© 2008 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pirker, R. Articles by Pereira, J. R. Search for Related Content PubMed Articles by Pirker, R. Articles by Pereira, J. R.

Abstract

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

Medical University of Vienna, Vienna, Austria; Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlic, Otwock, Poland; Asklepios Fachkliniken Muenchen-Gauting, Gauting, Germany; Centrum Onkologii - Instytut im Marii Sklodowskie, Warsaw, Poland; Wielkopolskie Centrum Chorob Pluc I Gruzlicy, Poznan, Poland; Samsung Medical Center, Seoul, Republic of Korea; Hospital Grosshansdorf, Hamburg, Germany; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Merck Serono, Darmstadt, Germany; Instituto do Cancer - Arnaldo Vieira de Carvalho, Sao Paulo, Brazil

3

Background: Epidermal growth factor receptor (EGFR) dysregulation is common in NSCLC and is associated with poorer prognosis. This phase III study assessed the efficacy and safety of the EGFR-targeted monoclonal antibody cetuximab in combination with cisplatin/vinorelbine (CV) compared with CV alone in advanced NSCLC. Methods: Patients with EGFR- detectable advanced NSCLC were randomized 1:1 to cetuximab (400 mg/m² initial dose, then 250 mg/m²/wk) plus C (80 mg/m² d1) and V (25 mg/m² d1, d8) q3w (arm A) or CV alone (arm B). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival, tumor response, disease control, and safety. Randomization was stratified by ECOG performance status (0/1 vs 2) and tumor stage (wet IIIb vs IV). Results: 1,125 patients were randomized: 557 to arm A, 568 to arm B, 70% male, median age 59 (18–83) years, 94% stage IV, 47% adenocarcinoma (AC), 34% squamous cell carcinoma (SCC), 83% ECOG 0/1. Survival analysis was performed after 868 events had occurred. OS was significantly improved in arm A (stratified log-rank test). Preliminary results of prespecified subgroup analyses suggest a greater benefit in Caucasians independent of histology and a general better prognosis in Asians. Analyses of secondary endpoints are ongoing. Conclusions: Cetuximab plus CV demonstrated superior survival over CV alone in patients with advanced EGFR-detectable NSCLC. There was a remarkable difference between the outcome of Asian and Caucasian patients. This is the first study to demonstrate a survival benefit of an EGFR- targeted agent in combination with platinum-based chemotherapy in advanced first-line NSCLC irrespective of histology and confirms the clinical relevance of cetuximab in NSCLC.

Abstract presentation from the 2008 ASCO Annual Meeting